The Economic Impact of the Pancreatography in the Endoscopic Treatment of Pancreatic Pseudocysts
1 other identifier
interventional
50
0 countries
N/A
Brief Summary
Pancreatic pseudocysts (PP) present as a complication that occurs in 5-15% of acute pancreatitis and 26-40% of chronic pancreatitis (1-3). To date the endoscopic drainage with endoscopic ultrasound (EUS) has replace the surgical treatment due to the similar success and complication rate but with a lower cost and short hospital stay (4-6). Regarding recurrence, it is important to know the anatomy of the main pancreatic duct (MPD). For this purpose, the endoscopic retrograde pancreatography (ERP) has been describe as a useful tool. In fact, many authors perform it before the endoscopic drainage while others wait several weeks after the drainage (7-9) with similar technical success (5,8). However, there are no studies that compare the technical difficulty and the total cost between these two approaches.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Aug 2015
Longer than P75 for not_applicable
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 1, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2020
CompletedFirst Submitted
Initial submission to the registry
July 28, 2020
CompletedFirst Posted
Study publicly available on registry
July 31, 2020
CompletedMarch 6, 2024
March 1, 2024
4.8 years
July 28, 2020
March 4, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
The impact of the pancreatography in the endoscopic treatment of pancreatic pseudocysts
Determine the impact of the timing performing an endoscopic pancreatography in relation of the drainage of pancreatic pseudocyst
6 weeks
Study Arms (2)
Same day
ACTIVE COMPARATORThe ERP will be performed the same day of the endoscopic drainage of PP
Other day
ACTIVE COMPARATORThe ERP will be performed 6 weeks after the endoscopic drainage of PP.
Interventions
Endoscopic cannulation of main pancreatic duct
Eligibility Criteria
You may qualify if:
- Pancreatic pseudocyst that fulfilled the Atlanta Classification
- Symptomatic pancreatic pseudocyst
- Informed consent obtained
You may not qualify if:
- Patient unwilling to participate
- Absence of duration time of the pancreatography procedure in the record
- Absence of the number of weeks between the drainage and the pancreatography
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Purpose
- DIAGNOSTIC
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal investigator
Study Record Dates
First Submitted
July 28, 2020
First Posted
July 31, 2020
Study Start
August 1, 2015
Primary Completion
May 1, 2020
Study Completion
May 1, 2020
Last Updated
March 6, 2024
Record last verified: 2024-03